Menu
CHMP adopts a positive opinion acknowledging that Jardiance® reduces the risk of CV death
- In the EMPA-REG OUTCOME® trial Jardiance® reduced the risk of cardiovascular (CV) death by 38 percent vs placebo in patients with type 2 diabetes (T2D) and established CV disease when added to standard of care
- The Committee for Medicinal Products for Human Use (CHMP) recommends to update the existing label of Jardiance® (empagliflozin) for the treatment of adults with insufficiently controlled T2D
- This is the first time the CHMP supports the use of a diabetes treatment for its effect on both glycaemic control and CV events
Dans la même rubrique :
Mercredi 19 Novembre 2025 - 15:00 Algérie : la BAD salue les grands chantiers lancés |
Mercredi 5 Novembre 2025 - 18:21 Tchad : Star Oil Tchad et Airtel Money s'allient pour accélérer l'inclusion financière |
Mardi 28 Octobre 2025 - 19:45 Tchad : Atelier de Formation sur l'Utilisation des Images par le Volet des Standards des Ménages (EHCVM) |
